EGFR and non-small cell lung carcinoma: Several ongoing phase II/III trials (ORCHARD, INSIGHT, SAVANNAH, and GEOMETRY) [18,22,23,24,25,26,27] are investigating combinations of targeted therapies in EGFR-mutant advanced NSCLC patients whose disease has progressed after osimertinib administration.